{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:29Z","timestamp":1787026529719,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Mesenchymal stromal cell (MSC) therapy is a promising treatment that allows for drug minimization in clinical kidney transplantation. While it is thought that MSCs rapidly go into apoptosis after infusion, clinical evidence for this is scarce since methods to detect cell death of infused cells in vivo are lacking. Cell-free DNA (cfDNA) has recently gained attention as a biomarker for cell death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we longitudinally measured cfDNA in plasma samples of the recipient, kidney donor, and allogeneic third-party MSC in the context of the Neptune study. cfDNA levels were measured at several time points before and after allogeneic MSC infusion in the 10 recipients who participated in the Neptune study. cfDNA ratios between the recipient, kidney graft, and MSC were determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed a peak in MSC-derived cfDNA 4 h after the first and second infusions, after which MSC-derived cfDNA became undetectable. Generally, kidney graft-derived cfDNA remained in the baseline-level range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our results support preclinical data that MSC are short-lived after infusion, also in a clinical in vivo setting, and are relevant for further research into the mechanism of action of MSC therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1240347","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T13:07:59Z","timestamp":1698930479000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC"],"prefix":"10.3389","volume":"14","author":[{"given":"Geertje J.","family":"Dreyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos JM.","family":"Drabbels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies EJ.","family":"Reinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Heidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000032","article-title":"Mesenchymal stromal cells to prevent fibrosis in kidney transplantation","volume":"19","author":"Reinders","year":"2014","journal-title":"Curr Opin Organ transplantation"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.316","article-title":"Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial","volume":"307","author":"Tan","year":"2012","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04950610","article-title":"Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility","volume":"6","author":"Perico","year":"2011","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2012-0114","article-title":"Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study","volume":"2","author":"Reinders","year":"2013","journal-title":"Stem Cells Trans Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16528","article-title":"Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study","volume":"21","author":"Reinders","year":"2021","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12132","article-title":"Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation","volume":"26","author":"Perico","year":"2013","journal-title":"Transplant Int Off J Eur Soc Organ Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12967-014-0331-x","article-title":"Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients","volume":"12","author":"Reinders","year":"2014","journal-title":"J Trans Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15910","article-title":"Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study","volume":"20","author":"Dreyer","year":"2020","journal-title":"Am J Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MOT.0000000000000035","article-title":"Mesenchymal stromal cells to promote kidney transplantation tolerance","volume":"19","author":"Casiraghi","year":"2014","journal-title":"Curr Opin Organ transplantation"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7828","volume":"9","author":"Galleu","year":"2017","journal-title":"Apoptosis mesenchymal stromal Cells induces Vivo recipient-mediated immunomodulation Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00297","article-title":"Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion","volume":"3","author":"Eggenhofer","year":"2012","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","article-title":"Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6","volume":"5","author":"Lee","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2006-0548","article-title":"Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism","volume":"25","author":"Djouad","year":"2007","journal-title":"Stem Cells (Dayton Ohio)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.03874.x","article-title":"Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells","volume":"156","author":"English","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002246","article-title":"Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells","volume":"109","author":"Sato","year":"2007","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00148","article-title":"The life and fate of mesenchymal stem cells","volume":"5","author":"Eggenhofer","year":"2014","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2779","article-title":"Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells","volume":"36","author":"de Witte","year":"2018","journal-title":"Stem Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13387","article-title":"Cell-free DNA: an upcoming biomarker in transplantation","volume":"15","author":"Gielis","year":"2015","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-8981(01)00665-9","article-title":"About the possible origin and mechanism of circulating DNA apoptosis and active DNA release","volume":"313","author":"Stroun","year":"2001","journal-title":"Clin Chim Acta"},{"key":"B20","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020193","article-title":"Donor-derived cell-free DNA in kidney transplantation as a potential rejection biomarker: A systematic literature review","volume":"10","author":"Martuszewski","year":"2021","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016091034","article-title":"Cell-free DNA and active rejection in kidney allografts","volume":"28","author":"Bloom","year":"2017","journal-title":"J Am Soc Nephrol JASN"},{"key":"B23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.kint.2021.11.034","article-title":"Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study","volume":"101","author":"Bu","year":"2022","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1681\/ASN.2021091191","article-title":"The trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies","volume":"33","author":"Halloran","year":"2022","journal-title":"J Am Soc Nephrol JASN"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1097\/TP.0000000000004482","article-title":"Understanding donor-derived cell-free DNA in kidney transplantation: an overview and case-based guide for clinicians","volume":"107","author":"Graver","year":"2022","journal-title":"Transplantation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12967-015-0700-0","article-title":"Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study","volume":"13","author":"Reinders","year":"2015","journal-title":"J Trans Med"},{"key":"B27","unstructured":"AlloSeq cfDNA assay Instructions for Use IFU090"},{"key":"B28","unstructured":"AlloSeq cfDNA software Instructions for Use IFU091"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40472-021-00349-8","article-title":"Donor-derived cell-free DNA for acute rejection monitoring in heart and lung transplantation","volume":"8","author":"Keller","year":"2021","journal-title":"Curr Transplant Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00837-3","article-title":"Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics","volume":"6","author":"Song","year":"2022","journal-title":"Nat BioMed Eng"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2021-0968","article-title":"Cell-free DNA as a solid-organ transplant biomarker: technologies and approaches","volume":"16","author":"Edwards","year":"2022","journal-title":"biomark Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s40778-022-00212-1","article-title":"Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal stromal\/stem cells and other common cellular therapeutics","volume":"8","author":"Cottle","year":"2022","journal-title":"Curr Stem Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.12.006","article-title":"Intravascular mesenchymal stromal\/stem cell therapy product diversification: time for new clinical guidelines","volume":"25","author":"Moll","year":"2019","journal-title":"Trends Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/stcltm\/szab005","article-title":"Improved MSC minimal criteria to maximize patient safety: A call to embrace tissue factor and hemocompatibility assessment of MSC products","volume":"11","author":"Moll","year":"2022","journal-title":"Stem Cells Trans Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1240347\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T13:08:01Z","timestamp":1698930481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1240347\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2023.1240347"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1240347","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"article-number":"1240347"}}